Redwire Partners with Eli Lilly and Company on Second Spaceflight Mission to Conduct Additional Research on Chronic Diseases Following Successful Results
Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today that it is partnering with Eli Lilly and Company (Lilly) on a second spaceflight mission using its in-space pharmaceutical manufacturing platform, PIL-BOX.
- Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today that it is partnering with Eli Lilly and Company (Lilly) on a second spaceflight mission using its in-space pharmaceutical manufacturing platform, PIL-BOX.
- On this second mission (PIL-02)Lilly researchers will be conducting an experiment aimed at accelerating the discovery of novel medicines against chronic diseases.
- Following the successful results of the PIL-01 experiment, which demonstrated that microgravity benefited insulin crystal growth, Lilly researchers will use the PIL-02 mission to expand their understanding of crystal formulations and how they impact overall drug discovery and development.
- The PIL-02 experiment will launch onboard SpaceX’s 30th cargo resupply services mission (SpX-30) for NASA to the International Space Station.